{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035028","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.026654+00:00","generated_at":"2026-06-04T16:56:22.381930+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SELLAS raises ~$20M in registered direct offering plus warrants priced at $1.535/share","bullets":["Gross proceeds of ~$20M from sale of 13,029,316 shares (or pre-funded warrants) at $1.535/share on Nasdaq.","Concurrent private placement of warrants to purchase up to 13,029,316 shares at $1.41, exercisable for 5.5 years.","Offering includes warrants exercisable immediately; closing expected March 19, 2024.","Net proceeds to fund R&D, working capital, and general corporate purposes.","A.G.P./Alliance Global Partners acting as sole placement agent with 7% cash fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035028","json":"https://secwatch.observer/filing/0001104659-24-035028.json","markdown":"https://secwatch.observer/filing/0001104659-24-035028.md","text":"https://secwatch.observer/filing/0001104659-24-035028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924035028/0001104659-24-035028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924035028/tm248987d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T16:56:22.381930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"201d306e2838ae58d29f79c007d4211aaf59c2eb","claim":"SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) (the “Placement Agent”) pursuant to which the Company engaged A.G.P. as the exclusive placement agent in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924035028/0001104659-24-035028-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Effective","value":"2024-03-15"}],"fact_type":"material_agreement"},{"claim_id":"87c2ce9262a0f9d33992176ceddf435391a2b78e","claim":"SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreement with institutional investors valued at approximately $20.0 million (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”), (i) an aggregate of 11,000,000 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) and (ii) an aggregate of 2,029,316 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) to the Investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924035028/0001104659-24-035028-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors"},{"label":"Value","value":"approximately $20.0 million"},{"label":"Effective","value":"2024-03-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}